NCT04260022 - Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions

Leukemia, Myeloid, ChronicMyeloid LeukemiaChronic Myeloid LeukemiaPhiladelphia Positive Acute Lymphoblastic LeukemiaB Cell Precursor Type Acute Leukemia

Interventions

DRUG

Ascentage Pharma HQP1351 bioavailable inhibitor

HQP1351 taken by mouth every other day

DRUG

Blinatumomab

Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).

Trial Locations (8)

21201

RECRUITING

University of Maryland, Baltimore

30322

RECRUITING

Winship Cancer Institute, Emory University, Atlanta

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

44195

RECRUITING

Cleveland Clinic, Cleveland

72758

RECRUITING

Highlands Oncology, Rogers

77030

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

98109

RECRUITING

Fred Hutchinson Cancer Research Center, Seattle